Form 4: Teva Pharmaceutical Industries Director Perry Nisen Acquires Restricted Share Units

Director Perry Nisen acquired 9,632 restricted share units of Teva Pharmaceutical Industries on June 6, 2024, which vest on June 6, 2025.

Summary

• On June 6, 2024, Perry Nisen, a director of Teva Pharmaceutical Industries Ltd., was granted 9,632 restricted share units.
• These restricted share units vest on June 6, 2025.
• Each restricted share unit represents the contingent right to receive one ordinary share or the cash value of one ordinary share, at the discretion of the Human Resources and Compensation Committee.
• Following the transaction, Nisen directly owns 9,632 ordinary shares represented by the restricted share units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to executive compensation. The grant of restricted share units is generally viewed as a positive sign of aligning management interests with shareholders, but it's not a major event.

Positives

• The grant of restricted share units to a director aligns their interests with those of the shareholders.
• The vesting period of one year could incentivize the director to contribute to the company's success over that time.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the granting of restricted share units suggests an ongoing commitment to incentivizing key personnel.

Industry Context

Executive compensation in the pharmaceutical industry often includes equity-based awards like restricted share units to align management's interests with shareholder value and incentivize long-term performance. This is a common practice among publicly traded companies like Teva.

Comparison to Industry Standards

• Companies like Pfizer, Johnson & Johnson, and Novartis also utilize restricted stock units as part of their executive compensation packages.
• The vesting schedules and terms of these grants are generally comparable across the industry, with vesting periods typically ranging from one to three years.
• The size of the grant relative to the director's overall compensation package would be a key factor in assessing its significance.

Stakeholder Impact

• Shareholders may view the grant of restricted share units as a positive sign, aligning the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's performance to realize the value of the restricted share units.

Key Dates